The Australian landscape of newborn screening in the genomics era

Abstract

In Australia, over 300,000 newborns undergo newborn bloodspot screening (NBS) annually, with approximately 1 in 1,000 identified with a rare but actionable condition through this pathway. Prior to 2018, the inclusion criteria for adding conditions in NBS panels was inconsistent nationally, leading to the development of the Australian National Newborn Bloodspot Screening Policy Framework. This framework promotes systematic and evidence-based inclusion of conditions using criteria closely informed by traditional Wilson and Junger screening principles. Current policy initiatives are focused on achieving national consistency in the conditions screened. NBS programs, initiated in the 1960s, have used a variety of techniques, including but not limited to tandem mass spectrometry and immunological assays. The acceleration of genomic technologies has the potential to greatly increase the number of conditions screened and match affected newborns with innovative treatment options, including advanced (gene, immune modulation, and RNA) therapies. This review describes the evolution, current status quo, and outlook for Australian NBS programs with a focus on the implications of wider adoption of genomic newborn screening (gNBS) in our culturally, geographically, and genetically diverse population. We discuss the potential for transformative benefits for families with children identified by gNBS and how this must be balanced against the potential for a range of unintended negative consequences. We emphasise the importance of a nationally agreed, coordinated, and streamlined approach to the addition and removal of conditions from Australian NBS programs, which considers the utility, cost, ethical, and equity aspects of gNBS.

Keywords

Newborn screening / Australia / expansion / genomic sequencing / ethics

References

[1] Human Genetics Society of Australasia. Counting conditions and summary of conditions screened by programme. Available from: https://hgsa.org.au/common/Uploaded%20files/pdfs/policies,%20position%20statements%20and%20guidelines/newborn%20screening/2023%20PL01%20Counting%20Conditions%20and%20Summary%20of%20Conditions%20Screened%20by%20Programme..pdf [Last accessed on 21 Nov 2023]

[2] Wilcken B.Newborn screening.Pathology2008;40:104-15.

[3] The Department of Health and Aged Care. Population-based screening framework. Available from: https://www.health.gov.au/resources/publications/population-based-screening-framework?language=en [Last accessed on 21 Nov 2023]

[4] Wilson JMG. Principles and practice of screening for disease. Geneva: World Health Organisation;1968. Available from: https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 21 Nov 2023]

[5] Coman D.Extended newborn screening: an update for the general paediatrician.J Paediatr Child Health2012;48:E68-72

[6] Franková V,Jansen ME.Regulatory landscape of providing information on newborn screening to parents across Europe.Eur J Hum Genet2021;29:67-78 PMCID:PMC7853088

[7] Australian Health Ministers’ Advisory Council. Newborn bloodspot screening national policy framework. Available from: https://www.health.gov.au/sites/default/files/documents/2020/10/newborn-bloodspot-screening-national-policy-framework.pdf [Last accessed on 21 Nov 2023]

[8] Kariyawasam D,Wiley V,Farrar MA.The implementation of newborn screening for spinal muscular atrophy: the Australian experience.Genet Med2020;22:557-65

[9] Kariyawasam DS,Sampaio H.Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.Lancet Child Adolesc Health2023;7:159-70

[10] Dangouloff T,Servais L.Newborn screening of neuromuscular diseases.Neuromuscul Disord2021;31:1070-80

[11] Shih STF,Wiley V,Farrar MA.Economic evaluation of newborn screening for severe combined immunodeficiency.Int J Neonatal Screen2022;8:44

[12] Shih STF,Wiley V,Wong M.Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency.Int J Neonatal Screen2022;8:45 PMCID:PMC9326684

[13] Huang X,Zhu L.Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates.Orphanet J Rare Dis2022;17:66 PMCID:PMC8862216

[14] Godler DE,Gamage D.Feasibility of screening for chromosome 15 imprinting disorders in 16 579 newborns by using a novel genomic workflow.JAMA Netw Open2022;5:e2141911. PMCID:PMC8728620

[15] Bourmaud A,Domon B.Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: principle and applications.Proteomics2016;16:2146-59.

[16] Holm IA,Ceyhan-Birsoy O.The babySeq project: implementing genomic sequencing in newborns.BMC Pediatr2018;18:225 PMCID:PMC6038274

[17] Roman TS,Roche MI.Genomic sequencing for newborn screening: results of the NC NEXUS project.Am J Hum Genet2020;107:596-611

[18] Ceyhan-Birsoy O,Machini K.Interpretation of genomic sequencing results in healthy and ill newborns: results from the babyseq project.Am J Hum Genet2019;104:76-93 PMCID:PMC6323417

[19] Sagan A,Rajan S,McKee M. Screening: when is it appropriate and how can we get it right? Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559794/ [Last accessed on 21 Nov 2023]

[20] Andermann A,Beauchamp S.Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.Bull World Health Organ2008;86:317-9

[21] Andermann A,Beauchamp S.Guiding policy decisions for genetic screening: developing a systematic and transparent approach.Public Health Genomics2010;14:9-16

[22] Andermann A,Déry V.Genetic screening: a conceptual framework for programmes and policy-making.J Health Serv Res Policy2010;15:90-7.

[23] Arah OA,Delnoij DM,Custers T.Conceptual frameworks for health systems performance: a quest for effectiveness, quality, and improvement.Int J Qual Health Care2003;15:377-98

[24] Australian Institute of Health and Welfare. Health expenditure Australia 2020-21. Available from: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2020-21/contents/spending-trends-by-sources [Last accessed on 21 Nov 2023]

[25] Cao M,Ayres S.Australian healthcare professionals' perspectives on the ethical and practical issues associated with genomic newborn screening.J Genet Couns2023;32:376-86

[26] Metz MP,Gerace RL,Luke CG.Newborn screening in South Australia: is it universal?.Med J Aust2003;179:412-5.

[27] Nolan-Isles D,Hunter K.Enablers and barriers to accessing healthcare services for aboriginal people in New South Wales, Australia.Int J Environ Res Public Health2021;18:3014 PMCID:PMC7999419

[28] D'Silva AM,Best S,Farrar MA.Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme.Dev Med Child Neurol2022;64:625-32. PMCID:PMC9299803

[29] Therrell BL,Loeber JG.Current status of newborn screening worldwide: 2015.Semin Perinatol2015;39:171-87.

[30] Department of Health and Aged Care. Expansion of newborn bloodspot screening. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/expansion [Last accessed on 21 Nov 2023]

[31] Commonwealth of Australia. The new frontier - delivering better health for all Australians. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Newdrugs/Report [Last accessed on 21 Nov 2023]

[32] Wilcken B,Hammond J.Screening newborns for inborn errors of metabolism by tandem mass spectrometry.N Engl J Med2003;348:2304-12.

[33] Hall PL,Mchugh DM.Postanalytical tools improve performance of newborn screening by tandem mass spectrometry.Genet Med2014;16:889-95 PMCID:PMC4262759

[34] Watson MS,Lloyd-Puryear MA,Rodney Howell R.Newborn screening: toward a uniform screening panel and system.Genet Med2006;8 Suppl 1:1S-252S

[35] Schulze A,Kohlmüller D,Mayatepek E.Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications.Pediatrics2003;111:1399-406

[36] Forny P,Ballhausen D.Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision.J Inherit Metab Dis2021;44:566-92 PMCID:PMC8252715

[37] Hertzog A,Pandithan D.3-Methylglutaconyl-CoA hydratase deficiency: when ascertainment bias confounds a biochemical diagnosis.JIMD Rep2022;63:568-74 PMCID:PMC9626669

[38] Thompson S,Selvanathan A.Treatment of HMG-CoA lyase deficiency-longitudinal data on clinical and nutritional management of 10 australian cases.Nutrients2023;15:531 PMCID:PMC9920477

[39] Rüfenacht V.Mini-review: challenges in newborn screening for urea cycle disorders.Int J Neonatal Screen2015;1:27-35

[40] California Department of Public Health. NEwborn screening program: disorders detectable by newborn screening. Available from: https://www.cdph.ca.gov/Programs/CFH/DGDS/Pages/nbs/NBS-Disorders-Detectable.aspx [Last accessed on 21 Nov 2023]

[41] Ryder B,Glamuzina E.New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: management challenges and potential therapeutic approaches.J Inherit Metab Dis2021;44:903-15.

[42] Health Resources & Services Administration. Previously nominated conditions. Available from: https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previous-nominations [Last accessed on 21 Nov 2023]

[43] Department of Health and Aged Care. What is screened in the program. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/what-is-screened [Last accessed on 21 Nov 2023]

[44] Department of Health and Aged Care. Delivering newborn bloodspot screening programs. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/delivering-programs [Last accessed on 21 Nov 2023]

[45] Farrar MA.Spinal muscular atrophy - the dawning of a new era.Nat Rev Neurol2020;16:593-4

[46] McPherson E. Postcode lottery: The screening test saving babies in some states but not others. Available from: https://www.9news.com.au/national/newborn-screening-australia-postcode-lottery-calls-for-heel-prick-test-to-be-expanded/39cad501-9109-4855-8c59-e30c700903a1 [Last accessed on 21 Nov 2023]

[47] Newborn screening: a blueprint for the future executive summary: newborn screening task force report.Pediatrics2000;106:386-8

[48] Bhattacharya K,Jaffe A.Rare diseases research and policy in Australia: On the journey to equitable care.J Paediatrics Child Health2021;57:778-81

[49] Australian Government Department of Health and Aged Care. National strategic action plan for rare diseases. Available from: https://www.health.gov.au/resources/publications/national-strategic-action-plan-for-rare-diseases [Last accessed on 21 Nov 2023]

[50] Department of Health and Aged Care. MRFF genomics health futures mission implementation plan. Available from: https://www.health.gov.au/resources/publications/mrff-genomics-health-futures-mission-implementation-plan?language=en [Last accessed on 21 Nov 2023]

[51] Australian Genomics. Genomic screening consortium for australian newborns (GenSCAN). Available from: https://www.australiangenomics.org.au/projects/genomic-screening-consortium-for-australian-newborns-genscan/ [Last accessed on 21 Nov 2023]

[52] Kingsmore SF,Kunard CM.A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases.Am J Hum Genet2022;109:1605-19

[53] Owen MJ,Hansen C.An automated 13.5 hour system for scalable diagnosis and acute management guidance for genetic diseases.Nat Commun2022;13:4057 PMCID:PMC9325884

[54] Nurchis MC,Riccardi MT.Whole genome sequencing diagnostic yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis, and GRADE assessment.Arch Public Health2023;81:93 PMCID:PMC10210272

[55] Sachdev R,Baynam GS.Paediatric genomic testing: navigating medicare rebatable genomic testing.J Paediatr Child Health2021;57:477-83 PMCID:PMC8049061

[56] Burdick KJ,Rives LC.Limitations of exome sequencing in detecting rare and undiagnosed diseases.Am J Med Genet A2020;182:1400-6 PMCID:PMC8057342

[57] Kirk EP,Boggs K.Gene selection for the Australian reproductive genetic carrier screening project (“Mackenzie's Mission”).Eur J Hum Genet2021;29:79-87 PMCID:PMC7852568

[58] Vears DF,Christodoulou J,Newson AJ.Are we ready for whole population genomic sequencing of asymptomatic newborns?.Pharmgenomics Pers Med2023;16:681-91 PMCID:PMC10321326

[59] White S,Fleming J.Expanding the Australian newborn blood spot screening program using genomic sequencing: do we want it and are we ready?.Eur J Hum Genet2023;31:703-11 PMCID:PMC10250371

[60] Johnston J,Goldenberg A,Parens E.Sequencing newborns: a call for nuanced use of genomic technologies.Hastings Center Report2018; 48 Suppl 2:S2-6. PMCID:PMC6901349

[61] Ross LF.Ethical issues in newborn sequencing research: the case study of babyseq.Pediatrics2019;144:e20191031 PMCID:PMC6889970

[62] Rothstein MA.Currents in contemporary bioethics.J Law Med Ethics2012;40:682-9

[63] Botkin JR.Whole genome sequencing and newborn screening.Curr Genet Med Rep2016;4:1-6 PMCID:PMC4847737

[64] Woerner AC,Vockley J.The use of whole genome and exome sequencing for newborn screening: challenges and opportunities for population health.Front Pediatr2021;9:663752 PMCID:PMC8326411

[65] Newson AJ.The promise of public health ethics for precision medicine: the case of newborn preventive genomic sequencing.Hum Genet2022;141:1035-43.

[66] Pichini A,Patch C.Developing a national newborn genomes program: an approach driven by ethics, engagement and co-design.Front Genet2022;13:866168 PMCID:PMC9195613

[67] Bhattacharjee A,Wyman SK.Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing.Genet Med2015;17:337-47

[68] Easteal S,Balboa RF.Equitable expanded carrier screening needs indigenous clinical and population genomic data.Am J Hum Genet2020;107:175-82

[69] Ko JM,Kang Y.A new integrated newborn screening workflow can provide a shortcut to differential diagnosis and confirmation of inherited metabolic diseases.Yonsei Med J2018;59:652-61 PMCID:PMC5990675

[70] Wojcik MH,Ceyhan-Birsoy O.Discordant results between conventional newborn screening and genomic sequencing in the babyseq project.Genet Med2021;23:1372-5

[71] Downie L,Lewis S.Principles of genomic newborn screening programs: a systematic review.JAMA Netw Open2021;4:e2114336 PMCID:PMC8293022

[72] Walker CE,Davis G.The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort.Genetics in Medicine2017;19:546-52 PMCID:PMC5440569

[73] Downie L,Lewis S.Exome sequencing in newborns with congenital deafness as a model for genomic newborn screening: the baby beyond hearing project.Genet Med2020;22:937-44

[74] Genetti CA,Robinson JO.Parental interest in genomic sequencing of newborns: enrollment experience from the babyseq project.Genet Med2019;21:622-30 PMCID:PMC6420384

[75] Martin AR,Foulger RE.PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels.Nat Genet2019;51:1560-5.

[76] Yeung A,Amor D. Baby Screen+ newborn screening (version 1.108). Available from: https://panelapp.agha.umccr.org/panels/3931/ [Last accessed on 21 Nov 2023]

[77] Johnson F,MacLeod R.Receiving results of uncertain clinical relevance from population genetic screening: systematic review & meta-synthesis of qualitative research.Eur J Hum Genet2022;30:520-31 PMCID:PMC9090782

[78] Boardman F.'We're kind of like genetic nomads': prents' experiences of biographical disruption and uncertainty following in/conclusive results from newborn cystic fibrosis screening.Soc Sci Med2022;301:114972

[79] Esquerda M,Lorenzo D.Ethical questions concerning newborn genetic screening.Clin Genet2021;99:93-8

[80] Financial Services Council. FSC Standard No. 11: moratorium on genetic tests in life insurance. Available from: www.fsc.org.au/resources-category/standard/1779-standard-11-moratorium-on-genetic-tests-in-life-insurance/file [Last accessed on 21 Nov 2023]

[81] Dhondt JL.Expanded newborn screening: social and ethical issues.J Inherit Metab Dis2010;33:S211-7

[82] Zacharias RL,King JS.The legal dimensions of genomic sequencing in newborn screening.Hastings Cent Rep2018;48 Suppl 2:S39-41

[83] Lakes KD,Lemke A.Maternal perspectives on the return of genetic results: context matters.Am J Med Genet A2013;161A:38-47 PMCID:PMC3535554

[84] Verma IC,Kohli S.Past, present & future scenario of thalassaemic care & control in India.Indian J Med Res2011;134:507-21 PMCID:PMC3237251

[85] Medical Services Advisory Committee. About MSAC. Available from: http://msac.gov.au/internet/msac/publishing.nsf/Content/about-msac [Last accessed on 21 Nov 2023]

[86] Medical Services Advisory Committee. Guidelines for preparing assessments for the Medical Services Advisory Committee. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/E0D4E4EDDE91EAC8CA2586E0007AFC75/$File/MSAC%20Guidelines-complete-16-FINAL(18May21).pdf [Last accessed on 21 Nov 2023]

[87] Potter BK,Entwistle V.Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report.Public Health Genomics2009;12:4-10 PMCID:PMC2790790

[88] Potter BK,Graham ID.Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening.Int J Technol Assess Health Care2008;24:412-22

[89] Rahimzadeh V,de Wert G.Exome/genome-wide testing in newborn screening: a proportionate path forward.Front Genet2022;13:865400 PMCID:PMC9289115

[90] Pharmaceutical Benefits Advisory Committee. About the guidelines. Available from: https://pbac.pbs.gov.au/information/about-the-guidelines.html [Last accessed on 21 Nov 2023]

[91] Medical Services Advisory Committee. Application No. 1573 - reproductive carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/4EF0E3C5A7CC9D05CA2584240009557E/$File/1573%20-%20Final%20PSD_Jul2020.pdf [Last accessed on 21 Nov 2023]

[92] Medical Services Advisory Committee. Application No. 1637 - expanded reproductive carrier testing of couples for joint carrier status of genes associated with autosomal recessive and X-linked conditions. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/58B9ED94DEC5BCDECA2586D500054D7E/$File/1637%20Final%20PSD_Jul2022_redacted_UpdatedConsultation_clean.pdf [Last accessed on 21 Nov 2023]

[93] Ulph F.Psychological and ethical challenges of introducing whole genome sequencing into routine newborn screening: lessons learned from existing newborn screening.New Bioeth2023;29:52-74

[94] Williams WA 2nd.The Harms of Carrier Status Identification: a cautionary warning against newborn sequencing.J Pediatr2020;224:22-3.

[95] Goldenberg AJ,Brosco JP.Including ELSI research questions in newborn screening pilot studies.Genet Med2019;21:525-33.

[96] Currier RJ.Newborn screening is on a collision course with public health ethics.Int J Neonatal Screen2022;8:51 PMCID:PMC9590071

[97] Kemper AR,Brosco JP.Ensuring the life-span benefits of newborn screening.Pediatrics2019;144:e20190904 PMCID:PMC7202673

[98] Sen K,Gropman AL.Select ethical aspects of next-generation sequencing tests for newborn screening and diagnostic evaluation of critically Ill newborns.Int J Neonatal Screen2021;7:76 PMCID:PMC8628939

[99] Clark CC.Expanding the notion of “benefit”: comparing public, parent, and professional attitudes towards whole genome sequencing in newborns.New Genetics and Society2022;41:96-115

[100] Yang L,Shen B.Newborn screening in the era of precision medicine. In: Shen B, editor. Translational informatics in smart healthcare. Singapore: Springer; 2017. pp. 47-61.